MedTrace Logo

Efficacy of Rifaximin in Preventing Campylobacteriosis

NCT02280044 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-11-20

Study results available
· View outcomes & findings →

Summary

This study is a randomized, double-blinded, placebo-controlled, in-patient trial evaluating the prophylactic efficacy of rifaximin against campylobacteriosis following challenge with C. jejuni.

Conditions

  • Dysentery
  • Diarrhea
  • Enteric Campylobacteriosis

Interventions

BIOLOGICAL

Rifaximin intervention

Rifaximin administered then Challenge with C jejuni

BIOLOGICAL

Placebo intervention

Placebo administered then Challenge with C jejuni

Sponsors & Collaborators

  • Naval Medical Research Center

    collaborator FED

  • Uniformed Services University of the Health Sciences

    collaborator FED

  • Johns Hopkins Bloomberg School of Public Health

    lead OTHER

Principal Investigators

  • Kawsar Talaat, M.D. · Johns Hopkins Bloomberg School of Public Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2016-08-09
Completion
2016-08-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02280044 on ClinicalTrials.gov